C. Gallardo

发表

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

M. Ooi, H. Ng, S. Ong, 2022, Cancers.

Peripheral T-Cell Lymphoma with Hypodiploidy 43, XY, - 6, -8, -10 in a 64-year-old Male: A Case Report

C. Gallardo, J. Relos, 2011 .

Low incidence of venous thrombosis but high incidence of arterial thrombotic complications among critically ill COVID-19 patients in Singapore

J. Low, W. Peh, V. K. Ho, 2020, Thrombosis Journal.

Rationalising red blood cell transfusions in advanced haematological malignancies: a patient-centred approach

B. E. Fan, D. Christopher, C. Gallardo, 2021, The Lancet Healthy Longevity.

A novel JAK2 R564* variant in a patient with thrombocytosis

Kol Jia Yong, B. Yan, Jianbiao Zhou, 2020, International journal of laboratory hematology.

Chronic dapsone use causing methemoglobinemia with oxidative hemolysis and dyserythropoiesis

P. Kuperan, C. Gallardo, B. Fan, 2021, American journal of hematology/oncology.

Compound Heterozygous Factor VII Deficiency c.1025G>A p.(Arg342Gln) With Novel Missense Variant c.194C>G p.(Ala65Gly)

L. Goh, K. Ong, L. Wong, 2022, Journal of hematology.

Myeloid and lymphoid vacuolation in VEXAS syndrome

P. Kuperan, L. Goh, L. W. Koh, 2021, American journal of hematology.

Single‐agent daratumumab for refractory POEMS syndrome

S. Chan, D. Christopher, A. Tso, 2022, American journal of hematology.